Citations (52)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Aalam Sohal & Kris V Kowdley. (2023) Primary Biliary Cholangitis: Promising Emerging Innovative Therapies and Their Impact on GLOBE Scores. Hepatic Medicine: Evidence and Research 15, pages 63-77.
Read now
Read now
Elizabeth M. Lamos, Megan Kristan, Maka Siamashvili & Stephen N. Davis. (2021) Effects of anti-diabetic treatments in type 2 diabetes and fatty liver disease. Expert Review of Clinical Pharmacology 14:7, pages 837-852.
Read now
Read now
Joost P.H. Drenth & Jörn M. Schattenberg. (2020) The nonalcoholic steatohepatitis (NASH) drug development graveyard: established hurdles and planning for future success. Expert Opinion on Investigational Drugs 29:12, pages 1365-1375.
Read now
Read now
Articles from other publishers (49)
Lianru Chen, Ya Chen, Bin Wang, Zhongcheng Yang, Zongyu Cai, Xuekun Wang, Lidan Sun, Zheng Li & Guangji Wang. (2023) Design, synthesis, and biological evaluation of deuterated indolepropionic acid derivatives as novel long-acting pan PPARα/γ/δ agonists. Bioorganic & Medicinal Chemistry 96, pages 117533.
Crossref
Crossref
Olufemi Aoko, Tobias Maharaj, Fiona Boland, Danny Cheriyan & John Ryan. (2023) Meta‐analysis: Impact of intragastric balloon therapy on NAFLD‐related parameters in patients with obesity. Alimentary Pharmacology & Therapeutics.
Crossref
Crossref
Da Hyun Lee, Jai J. Jee, Yu Seol Lee, Da Ye Kim, Ji Yun Bang, Hye Won Lee, Hong Koh & Soo Han Bae. (2023) Fecal microbiota transplantation improves hepatic fibro-inflammation via regulating oxidative stress in experimental NASH. Digestive and Liver Disease 55:11, pages 1521-1532.
Crossref
Crossref
Meijian Zhang, Emma Barroso, Maria Ruart, Lucía Peña, Mona Peyman, David Aguilar-Recarte, Marta Montori-Grau, Patricia Rada, Clara Cugat, Carla Montironi, Mohammad Zarei, Javier Jurado-Aguilar, Antoni Camins, Jesús Balsinde, Ángela M. Valverde, Walter Wahli, Xavier Palomer & Manuel Vázquez-Carrera. (2023) Elafibranor upregulates the EMT-inducer S100A4 via PPARβ/δ. Biomedicine & Pharmacotherapy 167, pages 115623.
Crossref
Crossref
Nahum Méndez-Sánchez, Carlos E. Coronel-Castillo & Ana L. Ordoñez-Vázquez. (2023) Current Therapies for Cholestatic Diseases. Biomedicines 11:6, pages 1713.
Crossref
Crossref
Sitara Niranjan, Brett E. Phillips & Nick Giannoukakis. (2023) Uncoupling hepatic insulin resistance – hepatic inflammation to improve insulin sensitivity and to prevent impaired metabolism-associated fatty liver disease in type 2 diabetes. Frontiers in Endocrinology 14.
Crossref
Crossref
Sumit Kumar Mandal, Sonakshi Puri, Banoth Karan Kumar, Mohammed Muzaffar-Ur-Rehman, Pankaj Kumar Sharma, Murugesan Sankaranarayanan & P. R. Deepa. (2023) Targeting lipid-sensing nuclear receptors PPAR (α, γ, β/δ): HTVS and molecular docking/dynamics analysis of pharmacological ligands as potential pan-PPAR agonists. Molecular Diversity.
Crossref
Crossref
Pritam Thapa, Sunil P. Upadhyay, Vikas Singh, Varun C. Boinpelly, Jianping Zhou, David K. Johnson, Prajwal Gurung, Eung Seok Lee, Ram Sharma & Mukut Sharma. (2023) Chalcone: A potential scaffold for NLRP3 inflammasome inhibitors. European Journal of Medicinal Chemistry Reports 7, pages 100100.
Crossref
Crossref
Dimitrios Kotsos & Konstantinos Tziomalos. (2023) Microsomal Prostaglandin E Synthase-1 and -2: Emerging Targets in Non-Alcoholic Fatty Liver Disease. International Journal of Molecular Sciences 24:3, pages 3049.
Crossref
Crossref
Georgios Sfikas & Ioannis Valsamidis. 2023. Non-alcoholic Fatty Liver Disease - New Insight and Glance Into Disease Pathogenesis. Non-alcoholic Fatty Liver Disease - New Insight and Glance Into Disease Pathogenesis.
Young-Sun Lee & Ekihiro Seki. (2023) In Vivo and In Vitro Models to Study Liver Fibrosis: Mechanisms and Limitations. Cellular and Molecular Gastroenterology and Hepatology 16:3, pages 355-367.
Crossref
Crossref
Cristina Zivko, Finja Witt, Andreas Koeberle, Gregor Fuhrmann & Paola Luciani. (2023) Formulating elafibranor and obeticholic acid with phospholipids decreases drug-induced association of SPARC to extracellular vesicles from LX-2 human hepatic stellate cells. European Journal of Pharmaceutics and Biopharmaceutics 182, pages 32-40.
Crossref
Crossref
Samantha Thifani Alrutz Barcelos, Amanda Souza Silva-Sperb, Helena Abadie Moraes, Larisse Longo, Bruna Concheski de Moura, Matheus Truccolo Michalczuk, Carolina Uribe-Cruz, Carlos Thadeu Schmidt Cerski, Themis Reverbel da Silveira, Valesca Dall'Alba & Mário Reis Álvares-da-Silva. (2023) Oral 24-week probiotics supplementation did not decrease cardiovascular risk markers in patients with biopsy proven NASH: A double-blind placebo-controlled randomized study. Annals of Hepatology 28:1, pages 100769.
Crossref
Crossref
Stephen D. H. Malnick, Pavel Alin, Marina Somin & Manuela G. Neuman. (2022) Fatty Liver Disease-Alcoholic and Non-Alcoholic: Similar but Different. International Journal of Molecular Sciences 23:24, pages 16226.
Crossref
Crossref
Ying Shi, Xiaoguang Yang, Shuyue Wang, Yulun Wu, Lihua Zheng, Yufang Tang, Yanhang Gao & Junqi Niu. (2022) Human umbilical cord mesenchymal stromal cell-derived exosomes protect against MCD-induced NASH in a mouse model. Stem Cell Research & Therapy 13:1.
Crossref
Crossref
Yuzo Koda, Nobuhiro Nakamoto & Takanori Kanai. (2022) Regulation of Progression and Resolution of Liver Fibrosis by Immune Cells. Seminars in Liver Disease 42:04, pages 475-488.
Crossref
Crossref
Mingmei Shao, Yifei Lu, Hongjiao Xiang, Junmin Wang, Guang Ji & Tao Wu. (2022) Application of metabolomics in the diagnosis of non-alcoholic fatty liver disease and the treatment of traditional Chinese medicine. Frontiers in Pharmacology 13.
Crossref
Crossref
Tieshan Teng, Shuai Qiu, Yiming Zhao, Siyuan Zhao, Dequan Sun, Lingzhu Hou, Yihang Li, Ke Zhou, Xixi Yu, Changyong Yang & Yanzhang Li. (2022) Pathogenesis and Therapeutic Strategies Related to Non-Alcoholic Fatty Liver Disease. International Journal of Molecular Sciences 23:14, pages 7841.
Crossref
Crossref
Hsin-Hsien Yu, Hao-Chen Wang, Mao-Chih Hsieh, Ming-Che Lee, Bor-Chyuan Su & Yan-Shen Shan. (2022) Exendin-4 Attenuates Hepatic Steatosis by Promoting the Autophagy-Lysosomal Pathway. BioMed Research International 2022, pages 1-7.
Crossref
Crossref
Manyu Zhao, Liqun Wang, Mengzhu Wang, Shijie Zhou, Ying Lu, Huijie Cui, Alexandra C. Racanelli, Ling Zhang, Tinghong Ye, Bisen Ding, Ben Zhang, Jinliang Yang & Yuqin Yao. (2022) Targeting fibrosis: mechanisms and clinical trials. Signal Transduction and Targeted Therapy 7:1.
Crossref
Crossref
Loren M. DeVito, Edward A. Dennis, Barbara B. Kahn, Gerald I. Shulman, Joseph L. Witztum, Sudeshna Sadhu, Joseph Nickels, Matthew Spite, Susan Smyth & Sarah Spiegel. (2022) Bioactive lipids and metabolic syndrome—a symposium report. Annals of the New York Academy of Sciences 1511:1, pages 87-106.
Crossref
Crossref
Naomi F. Lange, Vanessa Graf, Cyrielle Caussy & Jean-François Dufour. (2022) PPAR-Targeted Therapies in the Treatment of Non-Alcoholic Fatty Liver Disease in Diabetic Patients. International Journal of Molecular Sciences 23:8, pages 4305.
Crossref
Crossref
Deendyal Bhurta & Sandip B. Bharate. (2022) Styryl Group, a Friend or Foe in Medicinal Chemistry. ChemMedChem 17:7.
Crossref
Crossref
Mahak Arora, Nikolina Kutinová Canová & Hassan Farghali. (2022) mTOR as an eligible molecular target for possible pharmacological treatment of nonalcoholic steatohepatitis. European Journal of Pharmacology 921, pages 174857.
Crossref
Crossref
Ki Wung Chung, Ye Eun Cho, Seung-Jin Kim & Seonghwan Hwang. (2022) Immune-related pathogenesis and therapeutic strategies of nonalcoholic steatohepatitis. Archives of Pharmacal Research 45:4, pages 229-244.
Crossref
Crossref
Roger Bentanachs, Ana Magdalena Velázquez, Rosa María Sánchez, Marta Alegret, Juan Carlos Laguna & Núria Roglans. (2022) El ácido bempedoico como activador PPARα: Nuevas perspectivas para el tratamiento de la esteatosis hepática en un modelo experimental de rata hembra. Clínica e Investigación en Arteriosclerosis 34:2, pages 57-67.
Crossref
Crossref
Roger Bentanachs, Ana Magdalena Velázquez, Rosa María Sánchez, Marta Alegret, Juan Carlos Laguna & Núria Roglans. (2022) Bempedoic acid as a PPARα activator: New perspectives for hepatic steatosis treatment in a female rat experimental model. Clínica e Investigación en Arteriosclerosis (English Edition) 34:2, pages 57-67.
Crossref
Crossref
Gargi Dixit & Arati Prabhu. (2022) The pleiotropic peroxisome proliferator activated receptors: Regulation and therapeutics. Experimental and Molecular Pathology 124, pages 104723.
Crossref
Crossref
Man Zhao, Huazhong Xie, Hao Shan, Zhihua Zheng, Guofeng Li, Min Li & Liang Hong. (2022) Development of Thyroid Hormones and Synthetic Thyromimetics in Non-Alcoholic Fatty Liver Disease. International Journal of Molecular Sciences 23:3, pages 1102.
Crossref
Crossref
Dahae Lee, Tuy An Trinh, Myoung-Sook Shin & Ki Sung Kang. 2022. Recent Advancements in Microbial Diversity. Recent Advancements in Microbial Diversity
209
228
.
Ali Mahmoudi, Alexandra E. Butler, Tannaz Jamialahmadi & Amirhossein Sahebkar. (2021) Target Deconvolution of Fenofibrate in Nonalcoholic Fatty Liver Disease Using Bioinformatics Analysis. BioMed Research International 2021, pages 1-14.
Crossref
Crossref
Branka Filipovic, Snezana Lukic, Dragana Mijac, Marija Marjanovic-Haljilji, Marko Vojnovic, Jelena Bogdanovic, Tijana Glisic, Natasa Filipovic, Jamal Al Kiswani, Aleksandra Djokovic, Suncica Kapor, Slobodan Kapor, Zoran Bukumiric & Ana Starcevic. (2021) The New Therapeutic Approaches in the Treatment of Non-Alcoholic Fatty Liver Disease. International Journal of Molecular Sciences 22:24, pages 13219.
Crossref
Crossref
Lucia Mastrototaro & Michael Roden. (2021) Insulin resistance and insulin sensitizing agents. Metabolism 125, pages 154892.
Crossref
Crossref
Zhao Yang, Katherine Roth, Manisha Agarwal, Wanqing Liu & Michael C. Petriello. (2021) The transcription factors CREBH, PPARa, and FOXO1 as critical hepatic mediators of diet-induced metabolic dysregulation. The Journal of Nutritional Biochemistry 95, pages 108633.
Crossref
Crossref
Jingguo Li & Biguang Tuo. (2021) Current and Emerging Approaches for Hepatic Fibrosis Treatment. Gastroenterology Research and Practice 2021, pages 1-13.
Crossref
Crossref
Toshiaki Teratani, Kengo Tomita, Akinori Wada, Nao Sugihara, Masaaki Higashiyama, Kenichi Inaba, Kazuki Horiuchi, Yoshinori Hanawa, Shin Nishii, Akinori Mizoguchi, Rina Tanemoto, Suguru Ito, Yoshikiyo Okada, Chie Kurihara, Yoshihiro Akita, Kazuyuki Narimatsu, Chikako Watanabe, Shunsuke Komoto, Yuichi Oike, Soichiro Miura, Ryota Hokari & Takanori Kanai. (2021) Angiopoietin‐like protein 4 deficiency augments liver fibrosis in liver diseases such as nonalcoholic steatohepatitis in mice through enhanced free cholesterol accumulation in hepatic stellate cells. Hepatology Research 51:5, pages 580-592.
Crossref
Crossref
Emmanuel D. Dixon, Alexander D. Nardo, Thierry Claudel & Michael Trauner. (2021) The Role of Lipid Sensing Nuclear Receptors (PPARs and LXR) and Metabolic Lipases in Obesity, Diabetes and NAFLD. Genes 12:5, pages 645.
Crossref
Crossref
François Briand, Julie Maupoint, Emmanuel Brousseau, Natalia Breyner, Mélanie Bouchet, Clément Costard, Thierry Leste-Lasserre, Mathieu Petitjean, Li Chen, Audrey Chabrat, Virgile Richard, Rémy Burcelin, Caroline Dubroca & Thierry Sulpice. (2021) Elafibranor improves diet-induced nonalcoholic steatohepatitis associated with heart failure with preserved ejection fraction in Golden Syrian hamsters. Metabolism 117, pages 154707.
Crossref
Crossref
Shu‐Zhen Chen, Yan Ling, Le‐Xing Yu, Yu‐Ting Song, Xiao‐Fei Chen, Qi‐Qi Cao, Han Yu, Can Chen, Jiao‐Jiao Tang, Zhe‐Cai Fan, Yu‐Shan Miao, Ya‐Ping Dong, Jun‐Yan Tao, Satdarshan P.S. Monga, Wen Wen & Hong‐Yang Wang. (2021) 4‐phenylbutyric acid promotes hepatocellular carcinoma via initiating cancer stem cells through activation of PPAR‐α. Clinical and Translational Medicine 11:4.
Crossref
Crossref
Vinka Rupcic Rubin, Kristina Bojanic, Martina Smolic, Jurica Rubin, Ashraf Tabll & Robert Smolic. (2021) An Update on Efficacy and Safety of Emerging Hepatic Antifibrotic Agents. Journal of Clinical and Translational Hepatology 000:000, pages 1-11.
Crossref
Crossref
Saurabh Chandan, Babu P. Mohan, Shahab R. Khan, Antonio Facciorusso, Daryl Ramai, Lena L. Kassab, Neil Bhogal, Ravishankar Asokkumar, Gortrand Lopez-Nava, Stephanie McDonough & Douglas G. Adler. (2021) Efficacy and Safety of Intragastric Balloon (IGB) in Non-alcoholic Fatty Liver Disease (NAFLD): a Comprehensive Review and Meta-analysis. Obesity Surgery 31:3, pages 1271-1279.
Crossref
Crossref
May S. Freag, Bumseok Namgung, Maria E. Reyna Fernandez, Ermanno Gherardi, Shiladitya Sengupta & Hae Lin Jang. (2020) Human Nonalcoholic Steatohepatitis on a Chip. Hepatology Communications 5:2, pages 217-233.
Crossref
Crossref
Mohammad Zarei, David Aguilar-Recarte, Xavier Palomer & Manuel Vázquez-Carrera. (2021) Revealing the role of peroxisome proliferator-activated receptor β/δ in nonalcoholic fatty liver disease. Metabolism 114, pages 154342.
Crossref
Crossref
Clarissa Berardo, Laura Giuseppina Di Pasqua, Marta Cagna, Plinio Richelmi, Mariapia Vairetti & Andrea Ferrigno. (2020) Nonalcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: Current Issues and Future Perspectives in Preclinical and Clinical Research. International Journal of Molecular Sciences 21:24, pages 9646.
Crossref
Crossref
Jayanta Paul. (2020) Recent advances in non-invasive diagnosis and medical management of non-alcoholic fatty liver disease in adult. Egyptian Liver Journal 10:1.
Crossref
Crossref
Qiongming Liu, Junjie Yu, Liheng Wang, Yuliang Tang, Quan Zhou, Shuhui Ji, Yi Wang, Luis Santos, Rebecca A. Haeusler, Jianwen Que, Prashant Rajbhandari, Xiaoguang Lei, Luca Valenti, Utpal B. Pajvani, Jun Qin & Li Qiang. (2020) Inhibition of PU.1 ameliorates metabolic dysfunction and non-alcoholic steatohepatitis. Journal of Hepatology 73:2, pages 361-370.
Crossref
Crossref
Anne Fougerat, Alexandra Montagner, Nicolas Loiseau, Hervé Guillou & Walter Wahli. (2020) Peroxisome Proliferator-Activated Receptors and Their Novel Ligands as Candidates for the Treatment of Non-Alcoholic Fatty Liver Disease. Cells 9:7, pages 1638.
Crossref
Crossref
Noel C. Salvoza, Pablo J. Giraudi, Claudio Tiribelli & Natalia Rosso. (2020) Sex differences in non-alcoholic fatty liver disease: hints for future management of the disease. Exploration of Medicine 1:2, pages 51-74.
Crossref
Crossref
V.P. Shypulin, L.M. Parunyan, V.V. Tishhenko, О.К. Kolyada, O.M. Ponomarov & N.G. Melnyk. (2019) EFFECTIVENESS OF TREATMENT WITH PІOGLITAZONE IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE AND CONCOMITANT METABOLIC SYNDROME DEPENDING ON PRESENCE RS 1801282 (PRO12ALA) POLYMORPHISM IN GENE PPAR-γ. Medical Science of Ukraine (MSU) 15:1-2, pages 25-33.
Crossref
Crossref